GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Juby Chandy has resigned from his roles as Whole-Time Director and Chief Financial Officer (CFO) of GlaxoSmithKline Pharmaceuticals, effective from the close of business hours on March 11, 2026. He is stepping down because he has been appointed as Finance Head for the Asia Pacific region at GSK (the global parent group). The company disclosed this to the exchanges on March 16, 2026, under SEBI Listing Regulations. No successor has been named in this filing. The resignation follows the earlier announcement dated March 2, 2026.
The CFO is a key managerial personnel, and his departure creates a leadership gap in finance at a time when he is moving to a larger regional role within the parent group. While this is a normal internal promotion within GSK, investors may watch for the announcement of a replacement CFO, as prolonged vacancy at the finance helm can create short-term uncertainty.